What is it about?

GLP-1R agonists in patients with and without heart failure. Treatment with GLP1-RA did not reduce HF hospitalizations and mortality in patients with concomitant T2D and HF, but may prevent new-onset HF and mortality in patients with T2D without HF. The reduction of atherosclerotic events with GLP1-RA was not influenced by HF history status.

Featured Image

Why is it important?

GLP-1RA are very important in the treatment of Type 2 Diabetes and should not be neglect to be used

Perspectives

We need prospective designed studies

DAVIDE CARVALHO
Universidade do Porto

Read the Original

This page is a summary of: Glucagon‐like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta‐analysis of randomized placebo‐controlled outcome trials, Diabetes Obesity and Metabolism, February 2023, Wiley,
DOI: 10.1111/dom.14997.
You can read the full text:

Read

Contributors

The following have contributed to this page